

EQA round: AIM2/22 - Autoimmunity

Key: >>> ... marks correct (expected) result

> ... marks conditionally correct (acceptable) result

± ... marks the result not evaluated

N ... number of the results

Nrel ... relative number of the results

Test

Sample	Group	N	Result	N _{rel}
--------	-------	---	--------	------------------

Set 1

(560) ANA screening (cell nucleus) - prove

A1	(1) Fluorescent methods	>>>	73	Positive	91 %
	(2) EIA methods	>>>	6	Positive	7,5 %
	(99) Another measurement principle	>>>	1	Positive	1,3 %
	Total per sample: n = 80		Success: 100 %		
B1	(1) Fluorescent methods	>>>	72	Negative	90 %
			1	Positive	1,3 %
	(2) EIA methods	>>>	6	Negative	7,5 %
	(99) Another measurement principle	>>>	1	Negative	1,3 %
Total per sample: n = 80		Success: 99 %			

Total success: 99 %

(572) ANA screening (cell nucleus) - semi-quantity

A1	(0) Not specified	±	1	titre 80	1,5 %
		±	1	titre 160	1,5 %
		±	2	titre 320	3,0 %
		±	7	titre 640	10 %
		±	24	titre 1280	36 %
		±	32	titre 2560	48 %
Total per sample: n = 67		Success (only evaluated results): not assessed			
B1	(0) Not specified	±	1	Not specified	1,5 %
		±	48	titre 0 (not measurable)	72 %
		±	10	titre 40	15 %
		±	8	titre 80	12 %
Total per sample: n = 67		Success (only evaluated results): not assessed			

(561) ANA - type of fluorescence - nucleus

A1	(0) Not specified	>>>	54	Homogenous	75 %
			2	Homogenous; No fluorescence	2,8 %
		>>>	7	Homogenous; Coarse or fine speckled	9,7 %
		>>>	3	Homogenous; DFS 70 like	4,2 %
		>>>	4	Coarse or fine speckled	5,6 %
		>>>	2	Coarse or fine speckled; DFS 70 like	2,8 %
Total per sample: n = 72		Success: 97 %			
B1	(0) Not specified	>>>	70	No fluorescence	97 %
			2	Coarse or fine speckled	2,8 %
Total per sample: n = 72		Success: 97 %			

Total success: 94 %

(563) ANA screening (cytoplasm) - prove

A1	(1) Fluorescent methods	>>>	71	Negative	100 %
Total per sample: n = 71		Success: 100 %			
B1	(1) Fluorescent methods	>>>	71	Negative	100 %
Total per sample: n = 71		Success: 100 %			

Total success: 100 %

(573) ANA screening (cytoplasm) - semi-quantity

A1	(0) Not specified	±	49	titre 0 (not measurable)	77 %
		±	9	titre 40	14 %
		±	6	titre 80	9,4 %
Total per sample: n = 64		Success (only evaluated results): not assessed			
B1	(0) Not specified	±	49	titre 0 (not measurable)	77 %
		±	9	titre 40	14 %
		±	6	titre 80	9,4 %
Total per sample: n = 64		Success (only evaluated results): not assessed			

(564) ANA - type of fluorescence - cytoplasm

A1	(0) Not specified		1	Not specified	1,4 %
		>>>	69	No fluorescence	99 %
Total per sample: n = 70		Success: 99 %			
B1	(0) Not specified	>>>	70	No fluorescence	100 %
Total per sample: n = 70		Success: 100 %			

Total success: 99 %

Test

Sample	Group	N	Result	N _{rel}
--------	-------	---	--------	------------------

Set 2

(565) ANCA imunofluorescence - prove

A2	(0) Not specified	>>>	1	Positive	1,5 %
	(1) Fluorescent met. (ethanol)	>>>	52	Positive	78 %
	(2) Fluorescent met. (formalin)	>>>	6	Positive	9,0 %
	(99) Another measurement principle	>>>	8	Positive	12 %
Total per sample: n = 67		Success: 100 %			
B2	(0) Not specified	>>>	1	Negative	1,5 %
	(1) Fluorescent met. (ethanol)	>>>	52	Negative	78 %
	(2) Fluorescent met. (formalin)	>>>	6	Negative	9,0 %
	(99) Another measurement principle	>>>	8	Negative	12 %
Total per sample: n = 67		Success: 100 %			
Total success: 100 %					

(574) ANCA IF (ethanol) - semi-quantity

A2	(0) Not specified	±	2	titre 20	3,7 %
		±	7	titre 40	13 %
		±	12	titre 80	22 %
		±	13	titre 160	24 %
		±	9	titre 320	17 %
		±	10	titre 640	19 %
		±	1	titre 1280	1,9 %
Total per sample: n = 54		Success (only evaluated results): not assessed			
B2	(0) Not specified	±	42	titre 0 (not measurable)	78 %
		±	11	titre 20	20 %
		±	1	titre 40	1,9 %
Total per sample: n = 54		Success (only evaluated results): not assessed			

(578) ANCA IF (formalin) - semi-quantity

A2	(0) Not specified	±	1	titre 20	1,9 %
		±	7	titre 40	13 %
		±	12	titre 80	23 %
		±	14	titre 160	27 %
		±	15	titre 320	29 %
		±	2	titre 640	3,8 %
		±	1	titre 1280	1,9 %
Total per sample: n = 52		Success (only evaluated results): not assessed			
B2	(0) Not specified	±	41	titre 0 (not measurable)	79 %
		±	10	titre 20	19 %
		±	1	titre 40	1,9 %
Total per sample: n = 52		Success (only evaluated results): not assessed			

(566) ANCA - type of fluorescence

A2	(0) Not specified	>>>	52	Perinuclear fluorescence	80 %
			1	Perinuclear fluorescence; No fluorescence	1,5 %
		>>>	12	Perinuclear fluorescence; ANA	18 %
Total per sample: n = 65		Success: 98 %			
B2	(0) Not specified	>>>	65	No fluorescence	100 %
Total per sample: n = 65		Success: 100 %			
Total success: 98 %					

(569) anti-myeloperoxidase

A2	(1) Fluorescent methods	>>>	3	Positive	3,9 %
	(2) EIA methods	>>>	52	Positive	68 %
	(5) LIA, ILMA	>>>	9	Positive	12 %
	(6) Immunoblotting	>>>	9	Positive	12 %
	(99) Another measurement principle	>>>	3	Positive	3,9 %
Total per sample: n = 76		Success: 100 %			
B2	(1) Fluorescent methods	>>>	3	Negative	3,9 %
	(2) EIA methods	>>>	52	Negative	68 %
	(5) LIA, ILMA	>>>	9	Negative	12 %
	(6) Immunoblotting	>>>	9	Negative	12 %
	(99) Another measurement principle	>>>	3	Negative	3,9 %
Total per sample: n = 76		Success: 100 %			
Total success: 100 %					

(570) anti-proteinase III

A2	(1) Fluorescent methods	>>>	3	Negative	3,9 %
	(2) EIA methods	>>>	52	Negative	68 %
	(5) LIA, ILMA	>>>	9	Negative	12 %
	(6) Immunoblotting	>>>	9	Negative	12 %
	(99) Another measurement principle	>>>	3	Negative	3,9 %
Total per sample: n = 76		Success: 100 %			

Test

Sample	Group	N	Result	N _{rel}
B2	(1) Fluorescent methods	>>>	3 Negative	3,9 %
	(2) EIA methods	>>>	52 Negative	68 %
	(5) LIA, ILMA	>>>	9 Negative	12 %
	(6) Immunoblotting	>>>	9 Negative	12 %
	(99) Another measurement principle	>>>	3 Negative	3,9 %
Total per sample: n = 76		Success: 100 %		

Total success: 100 %

Set 3

(580) anti-ENA, antigen SS-A/Ro-60

A3	(1) Fluorescent methods	>>>	1 Positive	1,3 %
	(2) EIA methods	>>>	30 Positive	38 %
	(5) LIA, ILMA	>>>	2 Positive	2,5 %
	(6) Immunoblotting	>>>	44 Positive	56 %
	(99) Another measurement principle	>>>	2 Positive	2,5 %
Total per sample: n = 79		Success: 100 %		
B3	(1) Fluorescent methods	>>>	1 Negative	1,3 %
	(2) EIA methods	>>>	28 Negative	35 %
		1 Inconclusive result (borderline)	1,3 %	
		1 Positive	1,3 %	
	(5) LIA, ILMA	>>>	2 Negative	2,5 %
	(6) Immunoblotting	>>>	43 Negative	54 %
1 Inconclusive result (borderline)		1,3 %		
(99) Another measurement principle	>>>	2 Negative	2,5 %	
Total per sample: n = 79		Success: 96 %		

Total success: 96 %

(581) anti-ENA, antigen SS-B/La

A3	(1) Fluorescent methods	>>>	1 Negative	1,3 %
	(2) EIA methods	>>>	30 Negative	38 %
	(5) LIA, ILMA	>>>	2 Negative	2,5 %
	(6) Immunoblotting	>>>	43 Negative	54 %
		1 Inconclusive result (borderline)	1,3 %	
(99) Another measurement principle	>>>	2 Negative	2,5 %	
Total per sample: n = 79		Success: 99 %		
B3	(1) Fluorescent methods	>>>	1 Negative	1,3 %
	(2) EIA methods	>>>	30 Negative	38 %
	(5) LIA, ILMA	>>>	2 Negative	2,5 %
	(6) Immunoblotting	>>>	44 Negative	56 %
	(99) Another measurement principle	>>>	2 Negative	2,5 %
Total per sample: n = 79		Success: 100 %		

Total success: 99 %

(582) anti-ENA, antigen Scl-70

A3	(1) Fluorescent methods	>>>	2 Negative	2,5 %
	(2) EIA methods	>>>	30 Negative	38 %
	(5) LIA, ILMA	>>>	2 Negative	2,5 %
	(6) Immunoblotting	>>>	43 Negative	54 %
	(99) Another measurement principle	>>>	2 Negative	2,5 %
Total per sample: n = 79		Success: 100 %		
B3	(1) Fluorescent methods	>>>	2 Negative	2,5 %
	(2) EIA methods	>>>	29 Negative	37 %
		1 Positive	1,3 %	
	(5) LIA, ILMA	>>>	2 Negative	2,5 %
	(6) Immunoblotting	>>>	43 Negative	54 %
(99) Another measurement principle	>>>	2 Negative	2,5 %	
Total per sample: n = 79		Success: 99 %		

Total success: 99 %

(583) anti-ENA, antigen RNP

A3	(1) Fluorescent methods	>>>	1 Negative	1,3 %
	(2) EIA methods	>>>	30 Negative	38 %
	(5) LIA, ILMA	>>>	3 Negative	3,8 %
	(6) Immunoblotting	>>>	43 Negative	54 %
	(99) Another measurement principle	>>>	2 Negative	2,5 %
Total per sample: n = 79		Success: 100 %		
B3	(1) Fluorescent methods	>>>	1 Negative	1,3 %
	(2) EIA methods	>>>	30 Negative	38 %
	(5) LIA, ILMA	>>>	3 Negative	3,8 %
	(6) Immunoblotting	>>>	43 Negative	54 %
	(99) Another measurement principle	>>>	2 Negative	2,5 %

Test

Sample	Group	N	Result	N _{rel}
Total per sample: n = 79		Success: 100 %		
Total success: 100 %				

(584) anti-ENA, antigen Jo-1

A3	(1) Fluorescent methods	>>>	1	Negative	1,3 %
	(2) EIA methods	>>>	30	Negative	38 %
	(5) LIA, ILMA	>>>	3	Negative	3,8 %
	(6) Immunoblotting	>>>	43	Negative	54 %
	(99) Another measurement principle	>>>	2	Negative	2,5 %
Total per sample: n = 79		Success: 100 %			
Total success: 100 %					
B3	(1) Fluorescent methods	>>>	1	Negative	1,3 %
	(2) EIA methods	>>>	30	Negative	38 %
	(5) LIA, ILMA	>>>	3	Negative	3,8 %
	(6) Immunoblotting	>>>	43	Negative	54 %
	(99) Another measurement principle	>>>	2	Negative	2,5 %
Total per sample: n = 79		Success: 100 %			
Total success: 100 %					

(585) anti-centromere

A3	(0) Not specified	>>>	1	Negative	1,4 %
	(1) Fluorescent methods	>>>	8	Negative	11 %
				1	Positive
	(2) EIA methods	>>>	15	Negative	20 %
	(5) LIA, ILMA	>>>	2	Negative	2,7 %
	(6) Immunoblotting	>>>	45	Negative	61 %
(99) Another measurement principle	>>>	2	Negative	2,7 %	
Total per sample: n = 74		Success: 99 %			
B3	(0) Not specified	>>>	1	Negative	1,4 %
	(1) Fluorescent methods	>>>	9	Negative	12 %
				15	Negative
	(2) EIA methods	>>>	2	Negative	2,7 %
	(5) LIA, ILMA	>>>	36	Negative	49 %
				6	Inconclusive result (borderline)
(6) Immunoblotting	>>>	3	Positive	4,1 %	
(99) Another measurement principle	>>>	2	Negative	2,7 %	
Total per sample: n = 74		Success: 88 %			
Total success: 86 %					

Set 4**(588) anti-dsDNA immunofluor. - prove**

A4	(0) Not specified		9	Negative	15 %
		>	2	Inconclusive result (borderline)	3,3 %
		>>>	49	Positive	82 %
Total per sample: n = 60		Success: 85 %			
B4	(0) Not specified	>>>	60	Negative	100 %
Total per sample: n = 60		Success: 100 %			
Total success: 85 %					

(577) anti-dsDNA immunofluor. - semi-quantity

A4	(0) Not specified		± 5	titre 0 (not measurable)	9,8 %
			± 4	titre 10	7,8 %
			± 3	titre 20	5,9 %
			± 9	titre 40	18 %
			± 14	titre 80	27 %
			± 9	titre 160	18 %
			± 7	titre 320	14 %
Total per sample: n = 51		Success (only evaluated results): not assessed			
B4	(0) Not specified		± 40	titre 0 (not measurable)	78 %
			± 10	titre 10	20 %
			± 1	titre 40	2,0 %
Total per sample: n = 51		Success (only evaluated results): not assessed			

(589) anti-dsDNA other methods

A4	(2) EIA methods	>>>	46	Positive	77 %
		>>>	6	Positive	10 %
			4	Negative	6,7 %
	>	1	Inconclusive result (borderline)	1,7 %	
	>>>	2	Positive	3,3 %	
(99) Another measurement principle	>>>	1	Positive	1,7 %	
Total per sample: n = 60		Success: 93 %			
B4	(2) EIA methods	>>>	46	Negative	77 %
		>>>	6	Negative	10 %
		>>>	7	Negative	12 %

Summary statistics - qualitative results

(Groups: measurement principle)

EQA round: AIM2/22 - Autoimmunity

Deadline: 03.10.2022

Test

Sample	Group	N	Result	N _{rel}
B4	(99) Another measurement principle	>>> 1	Negative	1,7 %
Total per sample: n = 60		Success: 100 %		
Total success: 93 %				

Set 5**(591) anti-nukleosomes IgG**

A5	(2) EIA methods	>>> 40	Positive	70 %
	(6) Immunoblotting	>>> 17	Positive	30 %
Total per sample: n = 57		Success: 100 %		
B5	(2) EIA methods	>>> 40	Negative	70 %
	(6) Immunoblotting	>>> 17	Negative	30 %
Total per sample: n = 57		Success: 100 %		
Total success: 100 %				

st_kl

End of report

Printed: 13.10.2022